Fruzaqla (fruquintinib) — United Healthcare

Initial criteria

• Diagnosis of colorectal cancer
• Disease is advanced OR metastatic
• Patient has been previously treated with ALL of the following: fluoropyrimidine-based chemotherapy (e.g., capecitabine, 5-FU); oxaliplatin-based chemotherapy (e.g., CAPEOX, FOLFOX); irinotecan-based chemotherapy (e.g., FOLFIRI, FOLFIRINOX); anti-VEGF therapy (e.g., aflibercept, bevacizumab, ramucirumab)
• EITHER (a) Disease is RAS wild-type AND patient has been previously treated with an anti-EGFR therapy (e.g., cetuximab, panitumumab) OR (b) Disease is not RAS wild-type

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Fruzaqla therapy

Approval duration

12 months